search
Back to results

Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 Diabetes

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 3
Locations
Japan
Study Type
Interventional
Intervention
Vildagliptin
Placebo
Sponsored by
Novartis Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring Vildagliptin, Type 2 diabetes, HbA1c, Fasting plasma glucose

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with type 2 diabetes inadequately controlled with diet, exercise and oral anti-diabetic therapy.
  • HbA1c in the range of 7.0-10.0%
  • Body mass index in the range 20-35 kg/m2

Exclusion Criteria:

  • Type 1 diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes
  • Significant heart diseases

Other protocol-defined inclusion/exclusion criteria may apply

Sites / Locations

  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Vildagliptin

Placebo

Arm Description

In addition to their stable dose of metformin monotherapy, patients should take vildagliptin 50 mg twice daily.

In addition to their stable dose of metformin monotherapy, patients should take vildagliptin matching placebo.

Outcomes

Primary Outcome Measures

Change from baseline in glycosylated hemoglobin (HbA1c) at 12 weeks between treatment groups
HbA1c will be performed on a blood sample obtained by study personnel and measured by high-performance liquid chromatography (HPLC) performed at a central laboratory.

Secondary Outcome Measures

Change from baseline in HbA1c at 12 weeks within subgroups of metformin doses
HbA1c will be performed on a blood sample obtained by study personnel and measured by high-performance liquid chromatography (HPLC) performed at a central laboratory.
Change from baseline in Fasting plasma glucose (FPG) at 12 weeks
FPG will be performed on a blood sample obtained by study personnel and analyzed at a central laboratory.
Percentage of patients meeting Responder rates in HbA1c
Responder rates will be categorized by predefined HbA1c value at 12 weeks : Endpoint HbA1c ≤ 6.5% Endpoint HbA1c ≤ 7% Endpoint HbA1c ≤ 7% in patients with baseline HbA1c ≤ 8%
Number of patients with adverse events (including hypoglycemia), serious adverse events and death
The occurrence of adverse events will be sought by non-directive questioning of the patient at each visit. Adverse events are defined as appearance or worsening of any undesirable symptom, sign (including an abnormal laboratory finding), or medical conditions. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.

Full Information

First Posted
December 20, 2011
Last Updated
February 23, 2017
Sponsor
Novartis Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT01497522
Brief Title
Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 Diabetes
Official Title
A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 12 Weeks Treatment With LAF237 50 mg Bid to Placebo as Add-On Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
Study Type
Interventional

2. Study Status

Record Verification Date
February 2017
Overall Recruitment Status
Completed
Study Start Date
December 2011 (undefined)
Primary Completion Date
February 2013 (Actual)
Study Completion Date
February 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novartis Pharmaceuticals

4. Oversight

5. Study Description

Brief Summary
The purpose of the study is to evaluate the efficacy and safety of vildagliptin 50 mg bid as an add-on therapy to metformin in Japanese patients with T2DM. This study is being conducted to support registration of the fixed-dose combination of vildagliptin and metformin for the treatment of Type 2 diabetes mellitus (T2DM) in Japan.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
Vildagliptin, Type 2 diabetes, HbA1c, Fasting plasma glucose

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Enrollment
183 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Vildagliptin
Arm Type
Experimental
Arm Description
In addition to their stable dose of metformin monotherapy, patients should take vildagliptin 50 mg twice daily.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
In addition to their stable dose of metformin monotherapy, patients should take vildagliptin matching placebo.
Intervention Type
Drug
Intervention Name(s)
Vildagliptin
Other Intervention Name(s)
LAF237
Intervention Description
vildagliptin 50 mg twice daily
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Matching Placebo of vildagliptin 50 mg twice daily
Primary Outcome Measure Information:
Title
Change from baseline in glycosylated hemoglobin (HbA1c) at 12 weeks between treatment groups
Description
HbA1c will be performed on a blood sample obtained by study personnel and measured by high-performance liquid chromatography (HPLC) performed at a central laboratory.
Time Frame
Baseline to 12 weeks
Secondary Outcome Measure Information:
Title
Change from baseline in HbA1c at 12 weeks within subgroups of metformin doses
Description
HbA1c will be performed on a blood sample obtained by study personnel and measured by high-performance liquid chromatography (HPLC) performed at a central laboratory.
Time Frame
Baseline to 12 weeks
Title
Change from baseline in Fasting plasma glucose (FPG) at 12 weeks
Description
FPG will be performed on a blood sample obtained by study personnel and analyzed at a central laboratory.
Time Frame
Baseline to 12 weeks
Title
Percentage of patients meeting Responder rates in HbA1c
Description
Responder rates will be categorized by predefined HbA1c value at 12 weeks : Endpoint HbA1c ≤ 6.5% Endpoint HbA1c ≤ 7% Endpoint HbA1c ≤ 7% in patients with baseline HbA1c ≤ 8%
Time Frame
12 weeks
Title
Number of patients with adverse events (including hypoglycemia), serious adverse events and death
Description
The occurrence of adverse events will be sought by non-directive questioning of the patient at each visit. Adverse events are defined as appearance or worsening of any undesirable symptom, sign (including an abnormal laboratory finding), or medical conditions. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with type 2 diabetes inadequately controlled with diet, exercise and oral anti-diabetic therapy. HbA1c in the range of 7.0-10.0% Body mass index in the range 20-35 kg/m2 Exclusion Criteria: Type 1 diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes Significant heart diseases Other protocol-defined inclusion/exclusion criteria may apply
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis Pharmaceuticals
Organizational Affiliation
Novartis Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
Novartis Investigative Site
City
Kitakyushu
State/Province
Fukuoka
ZIP/Postal Code
800-0296
Country
Japan
Facility Name
Novartis Investigative Site
City
Kurume
State/Province
Fukuoka
ZIP/Postal Code
830-8543
Country
Japan
Facility Name
Novartis Investigative Site
City
Ohkawa-city
State/Province
Fukuoka
ZIP/Postal Code
831-0016
Country
Japan
Facility Name
Novartis Investigative Site
City
Kawasaki-city
State/Province
Kanagawa
ZIP/Postal Code
210-0014
Country
Japan
Facility Name
Novartis Investigative Site
City
Yokohama
State/Province
Kanagawa
ZIP/Postal Code
221-0802
Country
Japan
Facility Name
Novartis Investigative Site
City
Kyoto-city
State/Province
Kyoto
ZIP/Postal Code
615-0035
Country
Japan
Facility Name
Novartis Investigative Site
City
Takatsuki
State/Province
Osaka
ZIP/Postal Code
569-1096
Country
Japan
Facility Name
Novartis Investigative Site
City
Ageo-city
State/Province
Saitama
ZIP/Postal Code
362-8588
Country
Japan
Facility Name
Novartis Investigative Site
City
Bunkyo-ku
State/Province
Tokyo
ZIP/Postal Code
113-0031
Country
Japan
Facility Name
Novartis Investigative Site
City
Edogawa-ku
State/Province
Tokyo
ZIP/Postal Code
134-0084
Country
Japan
Facility Name
Novartis Investigative Site
City
Hachioji
State/Province
Tokyo
ZIP/Postal Code
192-0046
Country
Japan
Facility Name
Novartis Investigative Site
City
Kiyose
State/Province
Tokyo
ZIP/Postal Code
204-0021
Country
Japan
Facility Name
Novartis Investigative Site
City
Minato-ku
State/Province
Tokyo
ZIP/Postal Code
105-7390
Country
Japan
Facility Name
Novartis Investigative Site
City
Minato-ku
State/Province
Tokyo
ZIP/Postal Code
108-0075
Country
Japan
Facility Name
Novartis Investigative Site
City
Nerima-ku
State/Province
Tokyo
ZIP/Postal Code
177-0051
Country
Japan
Facility Name
Novartis Investigative Site
City
Shinagawa-ku
State/Province
Tokyo
ZIP/Postal Code
141-0032
Country
Japan
Facility Name
Novartis Investigative Site
City
Toshima-ku
State/Province
Tokyo
ZIP/Postal Code
171-0021
Country
Japan
Facility Name
Novartis Investigative Site
City
Fukuoka
ZIP/Postal Code
810-0001
Country
Japan
Facility Name
Novartis Investigative Site
City
Fukuoka
ZIP/Postal Code
819-0168
Country
Japan
Facility Name
Novartis Investigative Site
City
Kyoto
ZIP/Postal Code
607-8062
Country
Japan

12. IPD Sharing Statement

Citations:
PubMed Identifier
24604395
Citation
Odawara M, Hamada I, Suzuki M. Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus. Diabetes Ther. 2014 Jun;5(1):169-81. doi: 10.1007/s13300-014-0059-x. Epub 2014 Mar 7.
Results Reference
result

Learn more about this trial

Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 Diabetes

We'll reach out to this number within 24 hrs